May 08, 2026

Long-Term Risks Revealed for Older Survivors of Childhood Cancers

Survivors of childhood cancer who reach the age of 50 and beyond show continued elevated risks for premature mortality, subsequent cancers, and other chronic health conditions, according to a report p...

The ASCO Post

May 08, 2026

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

A cohort study showed that patients with melanoma who received BRAF or MEK inhibitor therapy commonly experienced hypertension and mild cardiac dysfunction, supporting baseline cardiotoxicity risk str...

The ASCO Post

May 08, 2026

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transpla...

The ASCO Post

May 08, 2026

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

The ASCO Post

May 08, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

May 08, 2026

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up.  

The ASCO Post

May 07, 2026

Curing Most Leukemias on the Horizon: A 5-Decade MD Anderson Perspective on Leukemia Research

With the accelerating pace of research progress in leukemia comes the challenge of timely translation of discoveries into clinical practice. This brief review by Hagop Kantarjian, MD, FASCO, and Emil ...

The ASCO Post

May 07, 2026

Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants

In an analysis of a single-center trial reported in a research letter in JAMA Oncology, Reiss et al identified long-term outcomes with rucaparib maintenance in patients with platinum-sensitive advance...

The ASCO Post

May 07, 2026

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

The ASCO Post

May 05, 2026

Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

The ASCO Post